Tom 8, Nr 2 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-10-05
Wyświetlenia strony 401
Wyświetlenia/pobrania artykułu 147
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Współczesne leczenie endometriozy — jaką rolę odgrywają gestageny?

Anna Nowak-Glück1, Piotr Sieroszewski1, Maria Szubert1
Ginekologia i Perinatologia Praktyczna 2023;8(2):64-73.

Streszczenie

Endometrioza jest chorobą powszechną, dotykającą około 6–10% kobiet w wieku reprodukcyjnym. Wiąże się
przede wszystkim z bolesnymi miesiączkami, dyspareunią, przewlekłym bólem miednicy mniejszej oraz niepłodnością.
Poza metodami operacyjnymi kluczową rolę odgrywa leczenie farmakologiczne w formie terapii empirycznej
lub uzupełniającej do leczenia chirurgicznego. W tym zakresie dostępnych jest kilka grup leków. Ze względu
na skuteczność, profil bezpieczeństwa i stosunkowo niewielką ilość skutków ubocznych czołowe miejsce wśród
nich zajmują progestageny, czyli syntetyczne pochodne progesteronu. Stosowane są w monoterapii, w doustnej
antykoncepcji dwuskładnikowej, w iniekcjach domięśniowych oraz systemie wewnątrzmacicznym. Niniejszy artykuł
stanowi przegląd podstawowych leków z grupy progestagenów połączony z opisem ich podstawowego działania.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril. 2012; 98(3): 591–598.
  2. Viganò P, Parazzini F, Somigliana E, et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004; 18(2): 177–200.
  3. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020; 382(13): 1244–1256.
  4. Menni K, Facchetti L, Cabassa P. Extragenital endometriosis: assessment with MR imaging. A pictorial review. Br J Radiol. 2016; 89(1060): 20150672.
  5. Koninckx PR, Ussia A, Adamyan L, et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019; 111(2): 327–340.
  6. Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019; 15(11): 666–682.
  7. Endometriosis. 2012.
  8. Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020; 26(4): 565–585.
  9. Arnal JF, Lenfant F, Metivier R, et al. Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. Physiol Rev. 2017; 97(3): 1045–1087.
  10. Donnez J, Smoes P, Gillerot S, et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998; 13(6): 1686–1690.
  11. Tesone M, Bilotas M, Barañao R, et al. The Role of GnRH Analogues in Endometriosis-Associated Apoptosis and Angiogenesis. Gynecologic and Obstetric Investigation. 2008; 66(Suppl. 1): 10–18.
  12. Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol. 2004; 160(8): 784–796.
  13. Gupta S, Agarwal A, Sekhon L, et al. Serum and peritoneal abnormalities in endometriosis: potential use as diagnostic markers. Minerva Ginecol. 2006; 58(6): 527–551.
  14. Chopra Seema. Endometrioza. In: Zimmer Mariusz, ed. Endometrioza. Edra Urban & Partner. ; 2021.
  15. Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril. 2005; 83(1): 171–181.
  16. Overview | Endometriosis: diagnosis and management | Guidance. : NICE.
  17. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022; 2022(2): hoac009.
  18. Han SJ, O'Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014; 20(4): 467–484.
  19. Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009; 35(6): 1069–1076.
  20. Tanaka Y, Mori T, Ito F, et al. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis. Int J Gynaecol Obstet. 2016; 135(2): 135–139.
  21. Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014; 93(3): 239–247.
  22. Makabe T, Koga K, Miyashita M, et al. Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells. J Reprod Immunol. 2017; 119: 44–48.
  23. Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019; 24(1): 61–70.
  24. Maia H, Haddad C, Pinheiro N, et al. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 2012; 4: 543–549.
  25. Wu D, Hu M, Hong Li, et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet. 2014; 290(3): 513–523.
  26. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017; 377(1): 28–40.
  27. Andres Md, Lopes LA, Baracat EC, et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015; 292(3): 523–529.
  28. Strowitzki T, Faustmann T, Gerlinger C, et al. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health. 2015; 7: 393–401.
  29. Köhler G, Faustmann TA, Gerlinger C, et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010; 108(1): 21–25.
  30. Momoeda M, Taketani Y, Terakawa N, et al. A randomized, double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis]. Japanese Pharmacology and Therapeutics. 2007; 35: 769–783.
  31. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012; 285(1): 167–173.
  32. Strowitzki T, Marr J, Gerlinger C, et al. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet. 2012; 117(3): 228–233.
  33. Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009; 91(3): 675–681.
  34. Huvinen E, Holopainen E, Heikinheimo O. Norethisterone and its acetate - what's so special about them? BMJ Sex Reprod Health. 2021; 47(2): 102–109.
  35. Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril. 2000; 74(1): 24–30.
  36. Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005; 84(5): 1375–1387.
  37. Africander D, Louw R, Verhoog N, et al. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception. 2011; 84(4): 423–435.
  38. Buggio L, Somigliana E, Barbara G, et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017; 18(15): 1569–1581.
  39. Matasariu DR, Lozneanu L, Dumitraşcu I, et al. Hormonal, apoptotic, proliferative and inflammatory markers' expression in Desogestrel-treated women with ovarian endometriosis. Rom J Morphol Embryol. 2022; 63(1): 137–144.
  40. Tanmahasamut P, Saejong R, Rattanachaiyanont M, et al. Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecol Endocrinol. 2017; 33(7): 534–539.
  41. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171–180.
  42. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002; 3(3): 211–224.
  43. Cezar TC, Schweppe KW, Pletzer KR, et al. The cost-effective, but forgotten, medical endometriosis therapy: a prospective, quasi-randomized study on progestin therapy. Facts Views Vis Obgyn. 2018; 10(4): 181.
  44. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005; 20(3): 789–793.
  45. Whitaker LHR, Williams ARW, Critchley HOD. Selective progesterone receptor modulators. Curr Opin Obstet Gynecol. 2014; 26(4): 237–242.
  46. Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2000(2): CD000068.
  47. Soares SR, Martínez-Varea A, Hidalgo-Mora JJ, et al. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril. 2012; 98(3): 529–555.
  48. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003; 46 Suppl 1(1-2): S7–SS16.



Ginekologia i Perinatologia Praktyczna